Feature Q&A with Jo Watson

Jo Watson the Consumer Rep of the Pharmaceutical Benefits advisory committee (PBAC) will be our guest to answer your questions about the recent non-recommendation of Risdiplam. Jo will be explaining why it is so important to fill in a consumer comment for the upcoming July meeting that will be looking at Nusinursen (Spinraza) for adults.

The 45 minute session will be held on Wednesday 19th May at 10.30am and Jo will be taking questions live on the call. She is very keen to hear from the adult community.

If you have questions that you would like to ask, please email them directly to Julie Cini at smaaa@smaaustralia.org.au so we are able to send these directly to Jo beforehand so she is able to get the relevant information if necessary.


Feature Q and A with Jo Watson

Feature Q and A with Jo Watson

Subscribe to our Newsletter